Blog
RSS FeedPosted by Michael Wonder on 25 Mar 2019
Melbourne's Peter MacCallum Cancer Centre to be home of 'the next great wave in treatment'
25 March 2019 - A new form of cancer treatment that uses cell therapy to attack the disease will become ...
Posted by Michael Wonder on 22 Mar 2019
PBAC report - Options for listing PD-(L)1 checkpoint inhibitors for multiple cancer indications on the PBS
22 March 2019 - The PBAC Report to the Minister for Health on “Options for listing PD(L)-1 checkpoint inhibitors for multiple ...
Posted by Michael Wonder on 21 Mar 2019
Enzyvant's investigational Farber disease enzyme replacement therapy, RVT-801, receives FDA fast track and rare paediatric disease designations
21 March 2019 - Enzyvant today announced that the U.S. FDA has granted are paediatric disease and fast track designations for ...
Posted by Michael Wonder on 21 Mar 2019
NICE terminates yet another assessment of a cancer medicine
20 March 2019 - This time it is pembrolizumab (Keytruda). ...
Posted by Michael Wonder on 21 Mar 2019
Promoting biosimilars up to health plans, manufacturers, doctors, Gottlieb says
21 March 2019 - As he wraps up his final weeks as commissioner of the FDA, Scott Gottlieb, MD, talked about ...
Posted by Michael Wonder on 21 Mar 2019
Kentucky launches probe into drug overcharges by pharmacy benefit managers
22 March 2019 - Kentucky Attorney General Andy Beshear said on Thursday he had launched an investigation into allegations that ...
Posted by Michael Wonder on 21 Mar 2019
Institute for Clinical and Economic Review releases draft evidence report on esketamine for treatment-resistant depression
21 March 2019 - Public comment period now open until 17 April 2019; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 21 Mar 2019
Mystery solved: the pharma-backed group with a lot to say on Trump’s pitch to end drug rebates
20 March 2019 - RetireSafe, a Washington-based advocacy group with ties to the drug industry, appears to be behind a ...
Posted by Michael Wonder on 21 Mar 2019
FDA approves new device for treating moderate to severe chronic heart failure in patients
21 March 2019 - The U.S. FDA today approved the Optimizer Smart system for treating patients with chronic, moderate-to-severe heart failure ...
Posted by Michael Wonder on 21 Mar 2019
Why Ontario parents could soon be paying more for prescription drugs
22 March 2019 - Some Ontario parents will be paying more for their kids’ medicine starting next month. Young adults ...
Posted by Michael Wonder on 21 Mar 2019
Struggling to stay alive: rising insulin prices cause diabetics to go to extremes
20 March 2019 - The escalating cost of insulin has desperate diabetics rationing medication, acquiring the drug from friends or getting ...
Posted by Michael Wonder on 21 Mar 2019
AbbVie is sued for using Humira patent deals to block competition in the U.S.
20 March 2019 - In a novel step, a New York union accused AbbVie and seven other drug makers of ...
Posted by Michael Wonder on 21 Mar 2019
Is Orkambi deal close? Vertex meets again today with NHS England
21 March 2019 - Campaigners hopes rise after three year wait. ...
Posted by Michael Wonder on 21 Mar 2019
Jazz Pharmaceuticals announces U.S. FDA approval of Sunosi (solriamfetol) for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea
20 March 2019 - Sunosi is the first and only dual-acting dopamine and norepinephrine re-uptake inhibitor approved by the FDA to ...
Posted by Michael Wonder on 20 Mar 2019
York man Paul Thomas-Peter says he could die because NHS won't fund drug
19 March 2019 - A York cancer patient says he could die because the NHS refuses to fund immunotherapy treatment ...
Posted by Michael Wonder on 20 Mar 2019
Unprecedented drug shortage linked to Brexit, NHS bosses say
20 March 2019 - Hospitals across England are experiencing medicine shortages due to "stockpiling and price pressure as the Brexit ...